Skip to main content

Table 1 Participants’ demographics

From: Safety and efficacy outcomes at 1 year after MitraClip therapy for percutaneous mitral valve repair in patients with severe mitral regurgitation: the Egyptian experience

Variables Total N = 20
Age (years) Mean ± SD 66.8 ± 10.5
Range 46-84
Gender Female 3 (15%)
Male 17 (85%)
BSA (m2) Mean ± SD 1.77 ± 0.2
Range 1.55-2.3
MR etiology Ischemic 11 (55%)
Functional 6 (30%)
Flail 3 (15%)
NYHA class pre I 0 (0%)
II 0 (0%)
III 15 (75%)
IV 5 (25%)
EuroSCORE Median (IQR) 11 (9-12.5)
Range 7-15
HAS-BLED score Median (IQR) 1 (1-2)
Range 0-4
Coronary angiography and intervention Normal CAG 9 (45%)
TVD for medical treatment 2 (10%)
LM 1 (5%)
PCI 7 (35%)
RCA 5 (25%)
LAD 4 (20%)
Non-significant CAD 2 (10%)
LCX 4 (20%)
  1. N Number, SD Standard deviation, IQR Interquartile range, BSA Body surface area, MR Mitral regurgitation, NYHA New York Heart Association, EuroSCORE European System for Cardiac Operative Risk Evaluation, HAS-BLED Hypertension, abnormal liver/renal function, stroke history, bleeding history or predisposition, labile INR, elderly, drug/alcohol usage, CAG Coronary angiography, TVD Triple-vessel disease, LM Left main coronary artery, PCI Percutaneous coronary intervention, RCA Right coronary artery, LAD Left anterior descending, CAD Coronary artery disease, LCX Left circumflex